Stratification of high-risk prostate cancer into prognostic categories: A european multi-institutional study

European Urology

Volumn 67, Issue 1, 2015, Pages 157-164

  Joniau, Steven ^a   Briganti, Alberto ^b   Gontero, Paolo ^c   Gandaglia, Giorgio ^b   Tosco, Lorenzo ^a   Fieuws, Steffen ^a   Tombal, Bertrand ^d   Marchioro, Giansilvio ^e   Walz, Jochen ^f   Kneitz, Burkhard ^g   Bader, Pia ^h   Frohneberg, Detlef ^h   Tizzani, Alessandro ^c   Graefen, Markus ^f   Van Cangh, Paul ^a   Karnes, R Jeffrey ⁱ   Montorsi, Francesco ^b   Van Poppel, Hein ^a   Spahn, Martin ^j  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^e UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g UNIVERSITY OF WÜRZBURG   (Germany)

^h General Hospital Karlsruhe   (Germany)

ⁱ MAYO CLINIC   (United States)

^j UNIVERSITY OF BERN   (Switzerland)

more..

Author keywords

High risk prostate cancer; Locally advanced prostate cancer; Risk groups; Risk stratification

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER PROGNOSIS; EUROPE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR;

EID: 84964199233     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.01.020     Document Type: Article

References (32)

1. NCCN guidelines on prostate cancer, version 1.2011. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician-gls/pdf/prostate.pdf.
2. A. Heidenreich, J. Bellmunt, and M. Bolla EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease Eur Urol 59 2011 61 71
3. F.H. Schroder, J. Hugosson, and M.J. Roobol Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
4. M. Bolla, H. van Poppel, and B. Tombal Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) Lancet 380 2012 2018 2027
5. G.P. Swanson, M.A. Hussey, and C.M. Tangen Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794 J Clin Oncol 25 2007 2225 2229
6. T. Wiegel, D. Bottke, and U. Steiner Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95 J Clin Oncol 27 2009 2924 2930
7. E.M. Messing, J. Manola, and J. Yao Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy Lancet Oncol 7 2006 472 479
8. T.B. Dorff, T.W. Flaig, and C.M. Tangen Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study J Clin Oncol 29 2011 2040 2045
9. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974
10. O. Yossepowitch, S.E. Eggener, and F.J. Bianco Jr. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods J Urol 178 2007 493 499 discussion 499
11. A.V. D'Amico, J. Moul, P.R. Carroll, L. Sun, D. Lubeck, and M.H. Chen Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era J Clin Oncol 21 2003 2163 2172
12. O. Yossepowitch, S.E. Eggener, and A.M. Serio Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy Eur Urol 53 2008 950 959
13. D. van den Ouden, W.C. Hop, and F.H. Schroder Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy J Urol 160 1998 1392 1397
14. H. Van Poppel, H. Goethuys, P. Callewaert, L. Vanuytsel, W. Van de Voorde, and L. Baert Radical prostatectomy can provide a cure for well-selected clinical stage T3 prostate cancer Eur Urol 38 2000 372 379
15. B.S. Carver, F.J. Bianco Jr., P.T. Scardino, and J.A. Eastham Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer J Urol 176 2006 564 568
16. S.E. Lerner, M.L. Blute, and H. Zincke Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity J Urol 154 1995 1447 1452
17. J.F. Ward, J.M. Slezak, M.L. Blute, E.J. Bergstralh, and H. Zincke Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome BJU Int 95 2005 751 756
18. S.J. Freedland, A.W. Partin, E.B. Humphreys, L.A. Mangold, and P.C. Walsh Radical prostatectomy for clinical stage T3a disease Cancer 109 2007 1273 1278
19. C.-Y. Hsu, S. Joniau, R. Oyen, T. Roskams, and H. Van Poppel Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience Eur Urol 51 2007 121 129 discussion 128-9
20. G.W. Hull, F. Rabbani, F. Abbas, T.M. Wheeler, M.W. Kattan, and P.T. Scardino Cancer control with radical prostatectomy alone in 1,000 consecutive patients J Urol 167 2002 528 534
21. M.J. Zelefsky, Y. Yamada, M.A. Kollmeier, A.M. Shippy, and M.A. Nedelka Long-term outcome following three-dimensional conformal/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer Eur Urol 53 2008 1172 1179
22. J. Walz, S. Joniau, and F.K. Chun Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy BJU Int 107 2011 765 770
23. M. Spahn, S. Joniau, and P. Gontero Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients Eur Urol 58 2010 1 7 discussion 8-11
24. D.Y. Lin, L.J. Wei, and Z. Ying Model-checking techniques based on cumulative residuals Biometrics 58 2002 1 12
25. P. Royston Explained variation for survival models Stata J 6 2006 83 96
26. P.J. Heagerty, and Y. Zheng Survival model predictive accuracy and ROC curves Biometrics 61 2005 92 105
27. M. Pintilie Competing risks: a practical perspective 2006 John Wiley & Sons Chichester, UK
28. A.J. Stephenson, M.W. Kattan, and J.A. Eastham Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition J Clin Oncol 24 2006 3973 3978
29. M. Wirth, C. Tyrrell, and K. Delaere Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up Prostate Cancer Prostatic Dis 10 2007 87 93
30. J.I. Epstein, W.C. Allsbrook Jr., M.B. Amin ISUP Grading Committee The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma Am J Surg Pathol 29 2005 1228 1242
31. A.V. D'Amico, M.H. Chen, W.J. Catalona, L. Sun, K.A. Roehl, and J.W. Moul Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors Cancer 110 2007 56 61
32. J. Huang, F.A. Vicini, and S.G. Williams Percentage of positive biopsy cores: a better risk stratification model for prostate cancer? Int J Radiat Oncol Biol Phys 83 2012 1141 1148